Inflammation associated with low 25-hydroxyvitamin D (25(OH)D) is associated with increased morbidity and mortality among HIVinfected patients with vitamin D deficiency. We investigated the association between 25(OH)D and soluble biomarkers among HIVinfected patients on stable antiretroviral therapy. This is a cross-sectional study. This study focuses on assessment in subjects 40 years or older on stable antiretroviral therapy (ART) for >3 months. Chemiluminescent immunoassay was used to determine plasma 25(OH)D levels. Plasma soluble biomarkers were measured by Luminex technology. Multivariable linear regression analysis was used to assess the associations between log 10 -25(OH)D and soluble biomarkers.
Introduction
High rates of low 25-hydroxyvitamin D (25(OH)D) have been reported among HIV-infected patients. This increased prevalence is multifactorial, involving traditional factors for 25(OH)D deficiency, metabolic complications associated with HIV, and pharmacologic effect of antiretroviral therapy. [1] Low 25(OH)D has been associated with increased morbidity and mortality among HIV-infected patients and is thought to be secondary to increased proinflammatory cytokines in the setting of low 25(OH)D levels. [2] We investigated the association between soluble biomarkers and 25(OH)D levels in patients enrolled in the in the Hawaii Aging with HIV Cardiovascular (HAHC-CVD) cohort, a 5-year prospective study of aging HIV-infected patients on stable antiretroviral therapy. More recent data have emerged demonstrating a possible U-shaped or a reverse J-shaped association between 25(OH)D and mortality-with increased risk of death in both low and high 25(OH)D levels. [3, 4] We analyzed whether higher-than-optimal 25(OH)D is associated with immune dysregulation and inflammation in the HAHC-CVD cohort.
Methods

Subjects and study design
This is a cross-sectional analysis of the entry data of the subjects enrolled into the HAHC-CVD cohort. Subjects had documented HIV infection, ≥40 years old, and on stable antiretroviral therapy for ≥3 months. Subjects who were recently hospitalized, had active infection, malignancy, or AIDS-defining illness at the time of enrolment were excluded. The study was approved by the Committee on Human Studies of the University of Hawaii and written informed consent was obtained from all participants. A full description of the cohort recruitment has been previously published and described elsewhere. Milliplex Human Cardiovascular Disease panels (EMD Millipore) were used to measure the following plasma soluble biomarkers: C-reactive protein (CRP), interferon-gamma (IFNg), interleukin-1beta (IL-1b), IL-6, IL-8, IL-10, matrix metallopeptidase-9 (MMP-9), monocyte chemoattractant protein-1 (MCP-1), myeloperoxidase (MPO), plasminogen activator inhibitor type 1 (PAI-1), serum amyloid A (SAA), serum amyloid P component (SAP), soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), tumor necrosis factoralpha (TNF-a), and vascular endothelial growth factor (VEGF).
Three different markers of arterial dysfunction were available in the database: carotid intima media thickness (cIMT), flowmediated dilatation (FMD), and coronary artery calcium (CAC). Methods utilized to obtain cIMT, FMD, and CAC have been previously published. [5] 
Statistical analyses
Simple and multivariable linear regression analyses were performed to identify whether 25(OH)D was associated with soluble biomarker levels. Multiple linear regression models were adjusted for the following variables that may affect cytokine levels: age, sex, white ethnicity, body mass index (BMI), hepatitis C coinfection, current smoking status, undetectable HIV RNA, and CD4 percent. Soluble biomarkers and 25(OH)D levels were logtransformed to improve normality of residuals. To investigate any possible nonlinear associations, spline regression analyses were performed and quadratic functions were fitted in the models.
Hawaii is located in the tropics (latitude 21 degree North) and has 2 seasons, summer (May 1-September 30) and winter (October 1-April 30). We have previously reported that seasonal variations in 25(OH)D levels in the HAHC-CVD cohort exist. [6] In brief, median 25(OH)D levels were higher among subjects enrolled in summer compared to winter (36.9 [25.0, 44.5] ng/mL vs. 29.6 [22.0, 38.0] ng/mL, P = 0.01]. However, the association between season and 25(OH)D was not preserved in the final multivariate regression models when adjusted for other factors affecting 25(OH)D levels, such as BMI and ethnicity. Hence, season was not included in the regression models of the present study. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, 2002-2012).
Results
Of 138 (Table 1) .
Interestingly, when analysis was restricted among subjects with low 25(OH)D (<20 ng/mL), univariable linear regression analysis showed that lower 25(OH)D was associated with higher cytokines, consistent with previously published studies (albeit not statistically significant): selectin (b = À1.65, P = 0.14), sVCAM (b = À1.06, P = 0. Markers of arterial dysfunction as assessed by cIMT and FMD were similar between subjects with 25(OH)D <20 ng/mL, 20 to 
Discussion
Low 25(OH)D is associated with occurrence of both AIDS and non-AIDS-defining events, disease progression, and increased mortality. [7] The Endocrine Society considers 25(OH)D ≥30 ng/ mL as the optimal level for bone health and muscle function, but the upper limit of normal remains controversial. [8] The detrimental effects of low 25(OH)D is thought to be from the inflammation associated with low vitamin D levels. In HIVinfected individuals, a recent publication by Hoffman et al showed that high 25(OH)D was associated with lower TNF-a. [9] Similarly, among subjects with TB-HIV co-infection, severe 25 (OH)D deficiency (<10 ng/mL) was associated with higher levels of TNF, IL-6, and IL-8. [10] In a subset of the EuroSIDA cohort, 25 (OH)D <10 ng/mL was associated with increased hsIL-6. [7] Among 322 HIV-infected subjects in Nepal, 25(OH)D <20 ng/ mL was associated with higher CRP levels. [11] All four studies show association between low 25(OH)D and higher proinflammatory markers. However, all 4 cohorts had low proportion of patients with 25(OH)D> 50 ng/mL. It is likely that these Figure 1 . Scatter plot demonstrating a J-shaped relationship between 25-hydroxyvitamin D and tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 after fitting a quadratic function. 25-hydroxyvitamin D levels in ng/mL, whereas TNF-alpha and IL-10 levels presented in pg/mL. Table 1 25-hydroxyvitamin D as predictor of soluble plasma biomarkers assessed using multiple linear regression models. 3 . This increase in total 25(OH) and free 1a,25(OH) 2 D 3 is implicated as the triggering events for toxicity, resulting in hypercalcemia and hyperphosphatemia. [12, 13] To prevent detrimental effects of high vitamin D, some authors suggest using 100 ng/mL as the higher limit of normal 25(OH)D, but a recent study demonstrated increased mortality in 25(OH)D levels as low as 50 ng/mL. [3] Data from vitamin D supplementation studies have shown that for serum 25(OH)D concentrations to exceed 100 nmol/L (40 ng/mL), total vitamin D supply of 4000 IU/day must be met. Adverse effects are typically seen beyond a total vitamin D supply of 250 mg (10,000 IU)/day. [14] In our cohort, we found a surprising high 13.7% (19 subjects) had 25 (OH)D >50 ng/mL. Although only 3 of these 19 subjects acknowledged vitamin D supplementation, it is highly possible that these high levels were from exogenous use.
(OH)D as continuous variable
Issues of vitamin D use was not the primary objective of the HAHC-CVD cohort and it is possible that more intensive queries into use of over-the-counter supplemental medications may have uncovered more evidence of vitamin D supplementation.
We found that levels >50 ng/mL are associated with higher levels of inflammatory markers, even after adjusting for traditional factors that may affect cytokine levels. Although we did not find any direct suggestion that levels >50 ng/mL was associated with markers of arterial injury, this relationship between high 25(OH)D levels and higher levels of inflammatory markers is of potential clinical concern and warrants further investigation in a larger cohort.
Interestingly, consistent with previous studies, lower levels of 25(OH)D showed a trend toward higher inflammatory markers in our cohort (albeit not statistically significant). This may further suggest that a J-shaped association between vitamin D and cytokines exist-with increased inflammation in both extremely high and low 25(OH)D. We do not have any subjects with 25 (OH)D <10 ng/mL, which limited the analysis of the association of low 25(OH)D and soluble biomarkers. This study is limited by its cross-sectional nature, the small number of subjects in the dataset, the retrospective nature of the study, and likely by incomplete clinical data on vitamin D supplementation.
In summary, we report for the first time that high 25(OH)D is associated with higher proinflammatory markers. Our data suggest that there may be dangers to indiscriminate oversupplementation with vitamin D, and that perhaps periodic monitoring of 25(OH)D levels may be prudent to ensure that patients' 25(OH)D do not go beyond optimal levels. More research is warranted to elucidate the implication of high 25(OH) D levels and higher levels of plasma biomarkers.
